Abbott’s Volt pulsed field ablation system — for the treatment of atrial fibrillation. The Volt system delivers high-energy electrical pulses to targeted areas of the heart to disrupt abnormal rhythms ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.

Pulsed field ablation (PFA) has been embraced as a catheter ablation modality with potential to be safer for atrial ...

Patients with atrial fibrillation, or AFib, are at increased risk for stroke.Many of them go on blood thinners, which can cause problems. But there is a relatively new device that is being used ...

Union City Commissioner Douglas Bine filed the suit in November of 2024 after losing his seat in a close election. New report reveals families in southern Ohio living on land at risk of causing cancer ...

Apple's atrial fibrillation (AFib) history feature on Apple Watch has been qualified by the FDA under its Medical Device Development Tools (MDDT) program, the first digital health technology feature ...

Abbott Laboratories' second-generation pulse field ablation device for atrial fibrillation has received European CE Mark approval earlier than expected, the North Chicago-based company said today. The ...

MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...

CHICAGO, Nov 11 (Reuters) - Johnson & Johnson's ablation device outperformed drug therapy for the heart rhythm disorder atrial fibrillation in a study that will be used to seek U.S. regulatory ...

AMSTERDAM -- Edoxaban (Savaysa) didn't improve outcomes for high-risk patients with subclinical atrial fibrillation (Afib)-like episodes detected by implanted cardiac devices, the NOAH-AFNET 6 trial ...

CHICAGO (Reuters) - Johnson & Johnson's ablation device outperformed drug therapy for the heart rhythm disorder atrial fibrillation in a study that will be used to seek U.S. regulatory approval for ...